The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.
U.S. markets slowest GDP growth in two years; Nikkei sell-off; Abbott Labs to buy St. Jude Medical; more earnings beats.
Mixed economic data from Europe; Shire makes a hostile bid for Baxalta; Neiman Marcus readies for IPO.